bit.bio

bit.bio is an award-winning human synthetic biology company whose mission is coding cells for novel cures. They have developed an end-to-end platform for creating any human cell type using their patent-protected opti-ox precision cell programming technology. This platform can deterministically program human iPSCs into chosen cell identities with unprecedented biological consistency at industrial scale, approximately 10 times faster than conventional methods. Their ioCells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate experimental timelines and reduce variability compared to traditional workflows.

Beyond research products, bit.bio is leveraging their platform to build a pipeline of txCells for cell therapies, potentially unlocking a new generation of medicines. The company has assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling, and cell therapy. Founded in 2016 as a spinout from the University of Cambridge, bit.bio is headquartered at the Babraham Research Campus. Their technology combines synthetic and stem cell biology for precise, efficient, and consistent reprogramming of human cells used in research, drug discovery, and cell therapy applications.